Balyasny Asset Management L.P. Sells 256,700 Shares of Standard BioTools Inc. (NASDAQ:LAB)

Balyasny Asset Management L.P. cut its holdings in shares of Standard BioTools Inc. (NASDAQ:LAB - Free Report) by 25.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 735,004 shares of the company's stock after selling 256,700 shares during the quarter. Balyasny Asset Management L.P. owned 0.20% of Standard BioTools worth $1,286,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. increased its stake in shares of Standard BioTools by 7.7% in the third quarter. JPMorgan Chase & Co. now owns 139,748 shares of the company's stock worth $270,000 after buying an additional 9,995 shares during the period. HighTower Advisors LLC increased its stake in shares of Standard BioTools by 13.0% in the fourth quarter. HighTower Advisors LLC now owns 92,791 shares of the company's stock worth $162,000 after buying an additional 10,690 shares during the period. Invesco Ltd. increased its stake in shares of Standard BioTools by 7.5% in the fourth quarter. Invesco Ltd. now owns 175,041 shares of the company's stock worth $306,000 after buying an additional 12,194 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Standard BioTools by 10.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 181,468 shares of the company's stock worth $318,000 after buying an additional 16,475 shares during the period. Finally, Takeda Pharmaceutical Co. Ltd. purchased a new position in shares of Standard BioTools in the fourth quarter worth $29,000. 53.74% of the stock is owned by hedge funds and other institutional investors.

Standard BioTools Stock Performance

Shares of NASDAQ LAB traded down $0.03 during mid-day trading on Monday, hitting $1.05. The stock had a trading volume of 896,321 shares, compared to its average volume of 2,140,838. Standard BioTools Inc. has a 1 year low of $0.95 and a 1 year high of $2.74. The business has a 50 day moving average price of $1.13 and a two-hundred day moving average price of $1.48. The firm has a market cap of $398.81 million, a P/E ratio of -1.48 and a beta of 1.80.

Wall Street Analyst Weigh In

Separately, KeyCorp downgraded shares of Standard BioTools from an "overweight" rating to a "sector weight" rating in a research note on Thursday, February 27th.

Insider Buying and Selling at Standard BioTools

In related news, Director Casdin Partners Master Fund, L acquired 4,820,959 shares of Standard BioTools stock in a transaction on Friday, February 28th. The shares were acquired at an average cost of $1.06 per share, with a total value of $5,110,216.54. Following the transaction, the director now owns 58,846,780 shares in the company, valued at $62,377,586.80. This trade represents a 8.92% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 23.16% of the company's stock.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.